Cartesian Therapeutics, Inc.
RNAC Healthcare Biotechnology
Cartesian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.9%, EPS fell 7.84% and free cash flow fell 6.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow RNAC
Cartesian Therapeutics, Inc. (RNAC) EV/Sales
As of 16 October 2026, Cartesian Therapeutics, Inc. (RNAC) trades at a EV/Sales of 56.5×. Over the past ten years it has ranged from −5.4× (August 2016) to 1,823× (December 2019); the current reading is higher than 70% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 30.8× | 891.80% |
| FY2024 | 3.1× | 65.79% |
| FY2023 | 1.9× | 257.94% |
| FY2022 | 0.5× | (83.51%) |
| FY2021 | 3.2× | (61.83%) |
| FY2020 | 8.3× | (4.48%) |
| FY2019 | 8.7× | (97.22%) |
| FY2018 | 313× | (53.11%) |
| FY2017 | 667× | 4,842.52% |
| FY2016 | 13.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 39.7× | 29.03% |
| Dec 2025 | 30.8× | (77.05%) |
| Sep 2025 | 134× | 3.02% |
| Jun 2025 | 130× | 2,306.05% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LYEL Lyell Immunopharma, Inc. compare | −550× |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.5× |
| IVVD Invivyd, Inc. compare | 0.7× |
| CGEN Compugen Ltd. compare | 0.8× |
| PRQR ProQR Therapeutics N.V. compare | 0.9× |
| NAGE Niagen Bioscience, Inc. compare | 1.0× |
| ADCT ADC Therapeutics SA compare | 1.5× |
| RNAC Cartesian Therapeutics, Inc. | 56.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)